Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans

Nuclear Medicine and Biology

Volumn 35, Issue 3, 2008, Pages 335-341

  Antenor Dorsey, Jo Ann V ^a   Markham, Joanne ^a   Moerlein, Stephen M ^a   Videen, Tom O ^a   Perlmutter, Joel S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F NMB; Graphical method

Indexed keywords

BENPERIDOL; DOPAMINE 2 RECEPTOR; FLUORINE 18;

ADULT; ARTERIAL BLOOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; FEMALE; HUMAN; KINETICS; MALE; POSITRON EMISSION TOMOGRAPHY; VALIDATION STUDY;

ADULT; BENPERIDOL; CALIBRATION; CAUDATE NUCLEUS; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, THEORETICAL; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RADIAL ARTERY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; REFERENCE STANDARDS; SIGNAL PROCESSING, COMPUTER-ASSISTED; SUBTRACTION TECHNIQUE;

EID: 40749138662     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.12.004     Document Type: Article

References (52)

1. Reisine T.D., Fields J.Z., Stern L.Z., Johnson P.C., Bird E.D., and Yamamura H.I. Alterations in dopaminergic receptors in Huntington's disease. Life Sci 21 (1977) 1123-1128
2. Lee T., Seeman P., Rajput A., Farley I.J., and Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273 (1978) 59-61
3. Strange P.G. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 8 (1993) 263-270
4. Burt D.R., Creese I., and Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196 (1977) 326-328
5. Owen F., Cross A.J., Crow T.J., Longden A., Poulter M., and Riley G.J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2 (1978) 223-226
6. Lee T., Seeman P., Tourtellotte W.W., Farley I.J., and Hornykeiwicz O. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274 (1978) 897-900
7. Perlmutter J.S., Stambuk M.K., Markham J., Black K.J., McGee-Minnich L., Jankovic J., et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 17 (1997) 843-850
8. Reisine T.D., Fields J.Z., and Yamamura H.I. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci 21 (1977) 335-343
9. In: Baron J.C., Comar D., Farde L., Martinot J.L., and Mazoyer B. (Eds). Brain dopaminergic systems: imaging with positron emission tomography (1991), Kluwer Academic Publishers, Boston Academic Publishers, Boston 5-38
10. Frost J.J., Smith A.C., Kuhar M.J., Dannals R.F., and Wagner Jr. H.N. In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 40 (1987) 987-995
11. Coenen H.H., Wienhard K., Stocklin G., Laufer P., Hebold I., Pawlik G., et al. PET measurement of D2 and S2 receptor binding of 3-N-[(2′-18F]fluoroethyl)spiperone in baboon brain. Eur J Nucl Med 14 (1988) 80-87
12. Perlmutter J.S., Moerlein S.M., Huang D.R., and Todd R. Non-steady state measurement of in vivo radioligand binding with positron emission tomography: comparison with in vitro binding. J Neurosci 11 (1991) 1381-1389
13. Seeman P., Guan H.C., and Niznik H.B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3 (1989) 96-97
14. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Fowler J.S., and Wolf A.P. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13 (1993) 350-356
15. Riccardi P., Li R., Ansari M.S., Zald D., Park S., Dawant B., et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31 (2006) 1016-1026
16. In: Reynolds J.E.F. (Ed). Martindale the extra pharmacopeia. 30th ed (1993), The Pharmaceutical Press, London 567
17. Peroutka S.J., and Synder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137 (1980) 1518-1522
18. Arnett C.D., Wolf A.P., Shiue C.Y., Fowler J.S., MacGregor R.R., Christman D.R., et al. Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. J Nucl Med 27 (1986) 1878-1882
19. Moerlein S.M., Laufer P., Stocklin G., Pawlik G., Wienhard K., and Heiss W.D. Evaluation of 75Br-labelled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography. Eur J Nucl Med 12 (1986) 211-216
20. Suehiro M., Dannals R.F., Scheffel U., Stathis M., Wilson A.A., Ravert H.T., et al. In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol. J Nucl Med 31 (1990) 2015-2021
21. Moerlein S.M., and Perlmutter J.S. Specific binding of 3N-(2′-[18F]fluoroethyl)benperidol to primate cerebral dopaminergic D2 receptors demonstrated in vivo by PET. Neurosci Lett 148 (1992) 97-100
22. Moerlein S.M., Perlmutter J.S., and Welch M.J. Specific, reversible binding of [18F]benperidol to baboon D2 receptors: PET evaluation of an improved 18F-labeled ligand. Nucl Med Biol 22 (1995) 809-815
23. Moerlein S.M., Perlmutter J.S., Markham J., and Welch M.J. In vivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding. J Cereb Blood Flow Metab 17 (1997) 833-845
24. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10 (1990) 740-747
25. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., and Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16 (1996) 834-840
26. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 27 (2000) 661-670
27. Moerlein S.M., Banks W.R., and Parkinson D. Production of fluorine-18 labeled (3-N-methyl)benperidol for PET investigation of cerebral dopaminergic receptor binding. Appl Radiat Isot 43 (1992) 913-917
28. Welch M.J., and Kilbourn M.R. A remote system for the routine production of oxygen-15 radiopharmaceuticals. J Lab Comp Radiopharm 22 (1985) 1193-1200
29. Mazoyer B., Trebossen R., Deutch R., Casey M., and Blohm K. Physical characteristics of the ECAT 953B/31: a new high resolution brain positron tomograph. IEEE Trans Med Imaging 10 (1991) 499-504
30. Spinks T.J., Jones T., Bailey D.L., Townsend D.W., Grootoonk S., Bloomfield P.M., et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 37 (1992) 1637-1655
31. Ollinger J.M. Model-based scatter correction for fully 3D PET. Phys Med Biol 41 (1996) 153-176
32. Martin W.R., Powers W.J., and Raichle M.E. Cerebral blood volume measured with inhaled C15O and positron emission tomography. J Cereb Blood Flow Metab 7 (1987) 421-426
33. 15O. II. Implementation and validation. J Nucl Med 24 (1983) 790-798
34. Videen T.O., Perlmutter J.S., Herscovitch P., and Raichle M.E. Brain blood volume, flow and oxygen utilization measured with O-15 radiotracers and positron emission tomography: revised metabolic computations. J Cereb Blood Flow Metab 7 (1987) 513-516
35. Woods R.P., Cherry S.R., and Mazziota J.C. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16 (1992) 620-633
36. Andersson J.L. How to obtain high-accuracy image registration: application to movement correction of dynamic positron emission tomography data. Eur J Nucl Med 25 (1998) 575-586
37. Woods R.P., Mazziotta J.C., and Cherry S.R. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 14 (1993) 536-546
38. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., and Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15 (1984) 217-227
39. Perlmutter J.S., Larson K.B., Raichle M.E., Markham J., Mintun M.A., Kilbourn M.R., et al. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab 6 (1986) 154-169
40. Parsey R.V., Slifstein M., Hwang D.R., Abi-Dargham A., Simpson N., Mawlawi O., et al. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab 20 (2000) 1111-1133
41. Hwang D.R., Narendran R., Huang Y., Slifstein M., Talbot P.S., Sudo Y., et al. Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates. J Nucl Med 45 (2004) 338-346
42. Siessmeier T., Zhou Y., Buchholz H.G., Landvogt C., Vernaleken I., Piel M., et al. Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med 46 (2005) 964-972
43. Varga J., and Szabo Z. Modified regression model for the Logan plot. J Cereb Blood Flow Metab 22 (2002) 240-244
44. Ghaemi M., Hiker R., Rudolf J., Sobesky J., and Heiss W.-D. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neuro Neurosurg Psych 73 (2002) 517-523
45. 11C]-raclopride PET study. J Neurol 250 (2003) 1219-1223
46. 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 31 (2004) 1128-1135
47. 11C]N-methylspiperone. J Nucl Med 41 (2000) 65-70
48. Lammertsma A.A., and Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 4 (1996) 153-158
49. Ichise M., Toyama H., Innis R.B., and Carson R.E. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22 (2002) 1271-1281
50. Sossi V., Holden J.E., Chan G., Krzywinski M., Stoessl A.J., and Ruth T.J. Analysis of four dopaminergic tracers kinetics using two different tissue input function methods. J Cereb Blood Flow Metab 20 (2000) 653-660
51. Suzuki A., Tashiro M., Kimura Y., Mochizuki H., Ishii K., Watabe H., et al. Use of reference tissue models for quantification of histamine H1 receptors in human brain by using positron emission tomography and [11c]doxepin. Ann Nucl Med 19 (2005) 425-433
52. Moerlein S.M., Perlmutter J.S., Cutler P.D., and Welch M.J. Radiation dosimetry of [18F](N-methyl) benperidol as determined by whole-body PET imaging of primates. Nucl Med Biol 24 (1997) 311-318